The FDA issued a warning over possible dental problems — including tooth decay, cavities, oral infections, and loss of teeth — with orally dissolving medications containing buprenorphine used for the treatment of opioid use disorder and pain. However, the agency noted that the “benefits for use outweigh these risks and oral care can help.”
In other FDA news, the agency approved a supplemental new drug application for brexpiprazole (Rexulti) for the treatment of schizophrenia in patients ages 13 to 17, Otsuka and Lundbeck announced.
A slew of new updates to the Affordable Care Act preventive healthcare guidelines are being implemented by the Health Resources and Services Administration, including expanded coverage for adolescent suicide risk screening, HHS said.
The FDA granted investigational new drug clearance for a clinical drug-drug interaction study of R-ketamine (PCN-101) with other drugs, atai Life Sciences said.
Psychiatrists landed the #7 spot on U.S. News & World Report‘s best-paying jobs list for 2022, with a median salary of $208,000 and an unemployment rate of only 6.2%.
In an observational study of 236 people who died by suicide in Washington State, 48% died by firearm. However, more than half of people who answered a prior question about firearm access from their primary care provider reported no access. (JAMA Network Open)
Which movies actually portray psychopaths accurately, according to psychiatrists? (IFLScience)
The 49-year-old man suspected of setting fire to South Africa’s Parliament buildings in Cape Town was committed to a psychiatric hospital and will undergo evaluation. (The New York Times)
Sponsored by Usona Institute, the Pacific Neuroscience Institute announced that it has begun participant enrollment for a new psilocybin clinical trial for major depressive disorder.